Amryt Pharma plc (AMYT)
Upgrades & Downgrades
Latest AMYT news
Poolbeg Pharma beefs up leadership; brings key players from succesful Amryt Pharma team
9 November 2023
In a strategic move to strengthen its management team, Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) has announced the appointment of key former executives from Amryt Pharma, underscoring its commitment ...
Amryt Pharma: Final Chance To Pick Up An Attractive CVR
11 April 2023
Amryt Pharma is being acquired at $14.50 per share and a contingent value right and is trading at $14.69. The contingent value right consists of 2 milestones that pay out $1 and $1.50 on certain condi...
Why Shares of Amryt Pharma Jumped This Week
12 January 2023
A takeover bid by an Italian pharmaceutical and healthcare company boosted Amryt's shares.
Acquisition Of Amryt Pharma: How To Profit From Orphan Drugs Developers
12 January 2023
Amryt Pharma plc will be acquired by Chiesi Farmaceutici S.p.A. Amryt Pharma is valued at $1.25 billion plus $225 million upon achievement of certain pipeline development milestones.
New Strong Sell Stocks for December 7th
7 December 2022
ABST, AMYT and ARCE have been added to the Zacks Rank #5 (Strong Sell) List on December 7, 2022.
New Strong Sell Stocks for November 17th
17 November 2022
BRFS, AOS and AMYT have been added to the Zacks Rank #5 (Strong Sell) List on November 17, 2022.
New Strong Sell Stocks for November 16th
16 November 2022
EGO, BRFS and AMYT have been added to the Zacks Rank #5 (Strong Sell) List on November 16, 2022.
New Strong Sell Stocks for November 10th
10 November 2022
AMYT, CHRD and BKI have been added to the Zacks Rank #5 (Strong Sell) List on November 10, 2022.
Amryt Pharma PLC (AMYT) Q3 2022 Earnings Call Transcript
5 November 2022
Amryt Pharma PLC (NASDAQ:AMYT ) Q3 2022 Earnings Conference Call November 3, 2022 8:30 AM ET Company Participants Simon Loughrey - Group Financial Controller Joseph Wiley - CEO & Director Rory Nealon ...